Vertex Pharmaceuticals Incorporated (VRTX) — Analyst outlook / Analyst consensus target is. Based on 55 analyst ratings, the consensus is bullish — 47 Buy, 8 Hold.
The consensus price target is $549.73 (low: $441.00, high: $607.00), representing an upside of 23.7% from the current price $444.28.
Analysts estimate Earnings Per Share (EPS) of $0.46 and revenue of $10.89B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-2.08 vs est $0.46 (missed -555.8%). 2025: actual $15.46 vs est $18.48 (missed -16.3%). Analyst accuracy: 29%.
VRTX Stock — 12-Month Price Forecast
$549.73
▲ +23.74% Upside
Average Price Target
Based on 55 Wall Street analysts offering 12-month price targets for Vertex Pharmaceuticals Incorporated, the average price target is $549.73, with a high forecast of $607.00, and a low forecast of $441.00.
The average price target represents a +23.74% change from the last price of $444.28.
Highest Price Target
$607.00
Average Price Target
$549.73
Lowest Price Target
$441.00
VRTX Analyst Ratings
Buy
Based on 55 analysts giving stock ratings to Vertex Pharmaceuticals Incorporated in the past 3 months
EPS Estimates — VRTX
29%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$2.08
vs Est $0.46
▼ 121.9% off
2025
Actual $15.46
vs Est $18.48
▼ 19.5% off
Profitability Outlook
Company has mixed profitability — some years profitable, some at a loss. EPS trend is improving.
Revenue Estimates — VRTX
99%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $11.020B
vs Est $10.890B
▲ 1.2% off
2025
Actual $12.075B
vs Est $11.985B
▲ 0.7% off
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
